Please assess the completion status of the following clinical trial:

Trial Title: Ospemifene vs. Conjugated Estrogens in the Treatment of Postmenopausal Sexual Dysfunction

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Interested in resuming or continuing sexual activity~* Greater than 12 months since last menstrual cycle or prior bilateral oophorectomy~* Dyspareunia as a vulvovaginal atrophy symptom~* Normal mammogram within 12 months prior to entry into the study~Exclusion Criteria:~* History or suspicion of breast carcinoma~* History of hormone-dependent tumor~* Genital bleeding of unknown cause~* Ongoing vaginal infection~* History of cerebrovascular accident (CVA), myocardial infarction (MI) or heart disease~* Uncontrolled hypertension (HTN) over 160/100~* Serious disease or chronic condition that may prevent completion of study~* Body Mass Index (BMI) over 40~* Hypercoagulable state, or currently on anticoagulant therapy~* Use of any exogenous sex hormone within three months from study entry, or during the study~* Pelvic surgery within the last 12 months

- Gender: FEMALE
- Minimum Age: 40 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Ospemifene (Type: EXPERIMENTAL): Women randomized to this arm will receive 60mg oral ospemifene, taken daily, for 12 weeks
- Estrogen (Type: ACTIVE_COMPARATOR): Women randomized to this arm will receive 0.5mg vaginal conjugated estrogens, placed vaginally twice per week, for 12 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).